Cellular cardiomyoplasty as supportive therapy in patients with heart disease
View Patent ↗The present invention provides a system for treating heart disease as a “bridge to recovery” using cellular cardiomyoplasty. The system is particularly useful in selecting and treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. Based on various clinical criteria, a patient is selected and optionally treated using cellular cardiomyoplasty to improve the patient's cardiac function. The cardiomyoplasty may be combined with other treatments such as medications or left ventricular assist devices. Preferably, the cellular cardiomyoplasty eliminates the need for invasive surgery such as by-pass grafting or cardiac transplantation. The invention also provides kits for use in selecting and treating patients using the inventive method.
1. A method of treating a patient with heart disease, the method comprising steps of: treating a patient suffering from heart disease using a left ventricular assist device; treating the patient using cellular cardiomyoplasty; and removing the left ventricular assist device from the heart, without orthotopic cardiac transplantation, when measurement of ventricular volume shows at least a 10% improvement.
2. The method of claim 1 , wherein the step of treating the patient using cellular cardiomyoplasty comprises administering cells to the heart of the patient.
3. The method of claim 2 , wherein the cells are selected from the group consisting of skeletal myoblasts, fetal cardiomyocytes, embryonic stem cells, and bone marrow stem cells.
4. The method of claim 2 , wherein the cells are autologous skeletal myoblasts.
5. The method of claim 1 , wherein the step of treating the patient using cellular cardiomyoplasty is performed before or while the patient is being treated using a left ventricular assist device.
6. The method of claim 1 , wherein the patient is suffering from acute heart disease.
7. The method of claim 1 , wherein the patient is suffering from chronic heart disease.
8. The method of claim 1 , wherein the heart disease is selected from the group consisting of coronary artery disease, valvular heart disease, myocarditis, heart failure, dilated ischemic heart failure, congestive heart failure, cardiomyopathy, dilated cardiomyopathy, myocardial infarction.
9. The method of claim 1 , wherein the number of cells administered ranges from 1×10 6 to 10×10 9 cells.
10. The method of claim 1 , wherein the number of cells administered ranges from 1×10 7 to 1×10 9 cells.
11. The method of claim 1 , wherein the cells are greater than 90% viable.
12. The method of claim 1 , wherein the cells are greater than 90% pure skeletal myoblasts.
13. The method of claim 1 , wherein the cells are greater than 80% pure skeletal myoblasts.
14. The method of claim 1 , wherein the step of treating the patient with a left ventricular assist device is terminated at least 1 week after the step of treating the patient with cellular cardiomyoplasty is performed.
15. The method of claim 1 , wherein the step of treating the patient with a left ventricular assist device is terminated at least 4 weeks after the step of treating the patient with cellular cardiomyoplasty is performed.
16. The method of claim 1 , wherein the step of treating the patient with a left ventricular assist device is terminated at least 8 weeks after the step of treating the patient with cellular cardiomyoplasty is performed.
17. The method of claim 1 , wherein the step of treating the patient with a left ventricular assist device is terminated at least 6 months after the step of treating the patient with cellular cardiomyoplasty is performed.
18. The method of claim 1 , wherein the step of treating the patient with a left ventricular assist device is terminated at least 12 months after the step of treating the patient with cellular cardiomyoplasty is performed.
19. The method of claim 1 , wherein the step of treating the patient with a left ventricular assist device is terminated at least 18 months after the step of treating the patient with cellular cardiomyoplasty is performed.
20. The method of claim 1 , wherein the step of treating the patient with a left ventricular assist device is terminated at least 24 months after the step of treating the patient with cellular cardiomyoplasty is performed.